Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

MLA

van der Laan, Louvina E., et al. “Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.” Antimicrobial Agents and Chemotherapy, vol. 66, no. 6, June 2022, p. e0226421. EBSCOhost, https://doi.org/10.1128/aac.02264-21.

APA

van der Laan, L. E., Garcia-Prats, A. J., Schaaf, H. S., Chirehwa, M., Winckler, J. L., Mao, J., Draper, H. R., Wiesner, L., Norman, J., McIlleron, H., Donald, P. R., Hesseling, A. C., & Denti, P. (2022). Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 66(6), e0226421. https://doi.org/10.1128/aac.02264-21

Chicago

van der Laan, Louvina E, Anthony J Garcia-Prats, H Simon Schaaf, Maxwell Chirehwa, Jana L Winckler, Jun Mao, Heather R Draper, et al. 2022. “Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.” Antimicrobial Agents and Chemotherapy 66 (6): e0226421. doi:10.1128/aac.02264-21.